Literature DB >> 21601112

[The new WHO classification of digestive neuroendocrine tumors].

Jean-Yves Scoazec1, Anne Couvelard.   

Abstract

A new classification of digestive neuroendocrine neoplasms has been formulated in the 2010 revision of the WHO classification of digestive tumors. The principles of this new classification are different from those used in the previous one and the terminology is quite novel. Five main categories are recognized: neuroendocrine tumor G1; neuroendocrine tumor G2; neuroendocrine carcinoma, small cell type; neuroendocrine carcinoma, large cell type; mixed adenoneuroendocrine carcinoma (a new term for mixed tumors). This new classification will change the habits of the clinicians, familiar with the previous classification, which formed the basis for deciding the therapeutic strategy and the type of patient management. Attention must be paid when establishing the concordance between the new classification and the previous one and when reclassifying a previously diagnosed case, now under follow-up. Recommendations are proposed for the redaction of the pathological reports in this period of transition.
Copyright © 2011. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Year:  2011        PMID: 21601112     DOI: 10.1016/j.annpat.2011.01.001

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  12 in total

1.  Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours.

Authors:  J Zou; Q Li; F Kou; Y Zhu; M Lu; J Li; Z Lu; L Shen
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

2.  Clinicopathological features of an ascending colon mixed adenoneuroendocrine carcinoma with clinical serosal invasion.

Authors:  Xi-Jun Liu; Jin-Shan Feng; Wen-Yu Xiang; Bin Kong; Ling-Mei Wang; Jin-Cheng Zeng; Yan-Fang Liang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 3.  Neuroendocrine Tumors of the Esophagus: State of the Art in Diagnostic and Therapeutic Management.

Authors:  Dimitrios Schizas; Aikaterini Mastoraki; George I Kirkilesis; Athanasios D Sioulas; Ioannis S Papanikolaou; Evangelos P Misiakos; Nikolaos Arkadopoulos; Theodore Liakakos
Journal:  J Gastrointest Cancer       Date:  2017-12

Review 4.  Novel PET tracers: added value for endocrine disorders.

Authors:  Sébastien Bergeret; Judith Charbit; Catherine Ansquer; Géraldine Bera; Philippe Chanson; Charlotte Lussey-Lepoutre
Journal:  Endocrine       Date:  2019-03-14       Impact factor: 3.633

5.  Primary high-grade neuroendocrine carcinoma emerging from an adenomatous polyp in the setting of familial adenomatous polyposis.

Authors:  Claire J Detweiler; Diana M Cardona; David S Hsu; Shannon J McCall
Journal:  BMJ Case Rep       Date:  2016-02-16

6.  Prognostic value of immunohistochemical factors in esophageal small cell carcinoma (ESCC): analysis of clinicopathologic features of 73 patients.

Authors:  Yigong Zhang; Cong Li; Ming Chen
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

7.  Factors related to long-term survival in patients affected by well-differentiated endocrine tumors of the pancreas.

Authors:  Riccardo Casadei; Claudio Ricci; Paola Tomassetti; Davide Campana; Francesco Minni
Journal:  ISRN Surg       Date:  2012-07-02

8.  Advanced gastric neuroendocrine carcinoma with an adenocarcinoma component.

Authors:  Masashi Miguchi; Masahiko Iseki; Kunihiko Shimatani
Journal:  Case Rep Gastroenterol       Date:  2012-01-25

9.  PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.

Authors:  Angela Lamarca; Daisuke Nonaka; Wolfgang Breitwieser; Garry Ashton; Jorge Barriuso; Mairéad G McNamara; Sharzad Moghadam; Jane Rogan; Wasat Mansoor; Richard A Hubner; Christopher Clark; Bipasha Chakrabarty; Juan W Valle
Journal:  Oncotarget       Date:  2018-02-12

Review 10.  Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature.

Authors:  Federica Gaiani; Nicola de'Angelis; Roberta Minelli; Stefano Kayali; Maria Clotilde Carra; Gian Luigi de'Angelis
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.